Program Description
Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease that remains underdiagnosed. In HCM, the left ventricle becomes smaller, stiffer, and unable to fill with blood, causing a reduction in the heart’s ability to pump and resulting in symptoms such as chest pain, dizziness, dyspnea, and syncope. Traditional therapies such as beta blockers, calcium channel blockers, and disopyramide are used for symptom control. However, in recent years, the discovery of the genetic pathology of HCM has led to the development of several targeted therapies with the first cardiac myosin inhibitor, mavacamten, receiving FDA approval in 2022 and another agent, aficamten under investigation. As integral members of the health care team, pharmacists must understand goals of therapy with novel agents, including improving exercise capacity and relieving hypercontractility symptoms, and the potential role of these agents in improving clinical outcomes in patients with HCM. This webinar will review guidelines for the management of HCM and clinical safety and efficacy data of novel and emerging therapies for HCM to equip pharmacists to educate patients and other health care team members about advances in HCM treatment and management.
Target audience: Health-system and specialty pharmacists
Type of activity: Application
Release date: November 30, 2022
Expiration date: November 30, 2023
Time to complete activity: 1 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the pathophysiology, specific risk factors, and typical presentation of patients with hypertrophic cardiomyopathy (HCM)
- Analyze mechanism of action, safety and efficacy data, and recommended management strategies from evidence-based guidelines for novel therapies for HCM to address underdiagnosis and the unmet clinical needs of patients
- Illustrate approaches for pharmacists to collaborate with the multidisciplinary care team in the management of adverse effects, patient counseling, and monitoring of patients with HCM
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
